By Sheeba M. | March 30, 2026
Cannabis Earnings Preview: Q1 2026 — What to Watch as MSOs Report
The cannabis earnings calendar heats up over the next few weeks, and investors have one primary question heading into Q1 2026 results: have the cost-cutting moves that MSO leadership teams promised actually shown up on the income statement? The answer matters — not just for individual stock performance, but for the sector’s credibility with institutional investors who are watching from the sidelines.
What the Numbers Probably Look Like
Wholesale flower prices remain depressed in most mature adult-use markets, and that’s a headwind no amount of operational efficiency can fully offset. Cannabis Benchmarks data shows February-to-March average pricing essentially flat — up just 0.1% — which means top-line growth at most MSOs will likely be modest unless retail volumes are accelerating meaningfully in newer markets.
Green Thumb Industries (GTBIF) enters earnings season in a relatively stronger position. The company has consistently posted positive EBITDA in its core Illinois and New Jersey markets, and management has been vocal about facility optimization — trimming excess canopy in oversupplied states rather than running at full blast into a price wall. If GTBIF posts another quarter of positive EBITDA while maintaining its retail footprint expansion, that will reinforce its position as the most operationally disciplined large MSO.
Organigram (OGI) is worth watching closely. The company has been executing on its cost-per-gram reduction target, and a successful quarter would validate its operational pivot. OGI does not have the geographic diversification of GTBIF or Curaleaf (CURLF), which makes execution consistency more important — there is less room for one weak market to hide behind another strong one.
Debt Loads Are the Real Story
Several MSOs entered 2026 with meaningfully improved balance sheets — or at least improvement relative to 2024. Trulieve (TCNNF) completed a significant debt exchange in late 2025, extending maturities and reducing near-term refinancing risk. That is a quiet positive that does not always show up in earnings headlines but matters enormously for financial stability over the next 18 months.
The companies that have not addressed their debt loads are more exposed. CURLF still carries a substantial debt burden from its aggressive acquisition strategy, and with interest rates elevated, the cost of that debt is a meaningful drag on free cash flow. Bulls will argue the Florida footprint and vertical integration justify the leverage — bears will point out that leverage in a commodity pricing environment is a dangerous combination.
What Could Surprise to the Upside
A few potential catalysts embedded in Q1 reports worth flagging: Safe Banking Act momentum has actually accelerated in Q1 2026, and if it passes, the impact on MSO cost of capital could be material. Banking access means cheaper debt, better vendor terms, and potentially institutional capital that currently sits on the sidelines due to compliance concerns. Any management commentary on banking access should be treated as significant.
Also watch for 280E reform language. If Democratic leadership advances the measure, even smaller MSOs that have been crushed by the tax code could see meaningful EBITDA improvement without needing to move a single additional gram of product. This is a legislative tailwind, not an operational one — but it could move stocks before the actual earnings prints.
What Could Go Wrong
The bear case for Q1 is straightforward: wholesale price compression continues, cost cuts prove insufficient to offset revenue pressure, and one or more MSOs guides down for the full year. That scenario would likely trigger a sector-wide selloff and renewed pressure on Canopy Growth (CGC), which is already trading near multi-year lows and has limited room to maneuver before covenant issues become a serious concern.
Track all Q1 2026 earnings results and analyst reactions on the Weedstock real-time cannabis stock tracker.
Sources
- Cannabis Benchmarks – U.S. Cannabis Spot Index weekly pricing data
- SEC EDGAR – MSO 10-K and 10-Q filings for debt and revenue data
Related Articles
Track cannabis stocks with the Weedstock Real-Time Tracker